Hostname: page-component-6d856f89d9-8l2sj Total loading time: 0 Render date: 2024-07-16T05:11:54.819Z Has data issue: false hasContentIssue false
  • English
  • Français

Prognostic Factor Analysis and Treatment Results of Ovarian Cancer in Japan

Published online by Cambridge University Press:  10 March 2009

Kazunori Ochiai ,
Hiroshi Sasaki ,
Yoshiteru Terashima  and
Masanori Fukushima
Kazunori Ochiai
Affiliation:
The Jikei University School of Medicine
Hiroshi Sasaki
Affiliation:
The Jikei University School of Medicine
Yoshiteru Terashima
Affiliation:
The Jikei University School of Medicine
Masanori Fukushima
Affiliation:
Aichi Cancer Center
Get access Rights & Permissions [Opens in a new window]

Abstract

Prognostic factors were analyzed among women with ovarian cancer. Stage, histologic subtype and grade, age, performance status, residual tumor size, and platinum-based chemotherapy were factors that significantly influenced the survival rate. Based on these findings, we performed maximal cytoreductive surgery and gave dose-intensified platinum-based chemotherapy to patients with advanced disease and were able to improve survival rate significantly.

Type
Special Section: Assessing Nursing and Technology
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 3 , Summer 1994 , pp. 406 - 425
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Baak, J. P., Langley, F. A., Talerman, X., et al. Intrapathologist and interpathologist disagreement in ovarian tumor grading and typing. Analytical and Quantitative Cytology and Histology, 1986, 8, 354–57.Google ScholarPubMed
2.Cavaletti, G., & Marzorati, L.Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer, 1992, 69, 203–07.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
3.Dembo, A., & Bush, R.Choice of postoperative therapy based on prognostic factors. International Journal of Radiation Oncology, Biology, Physics, 1982, 8, 893–97.Google Scholar
4.Dembo, A., Davy, M., Stenwig, A., et al. Prognostic factors in patients with stage I epithelial ovarian carcinoma. Obstetrics and Gynecology, 1990, 75, 263–73.Google Scholar
5.De Re, F., Fontanelli, R., Raspagliesi, F., et al. Pelvic and para-aortic lymphadenectomy in cancer of the ovary. Bailliere's Clinical Obstetrics and Gynaecology, 1989, 3, 131–42Google Scholar
6.Edmonson, J. H., Fleming, T. R., Decker, D. G., et al. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal disease. Cancer Treatment Report, 1979, 63, 241–47.Google Scholar
7.Gallager, H. S.Prognostic importance of histologic type in ovarian carcinoma. National Cancer Institute Monogram, 1975, 42, 13–14.Google Scholar
8.Goldie, J. H., Coldman, J. A.A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Report, 1979, 63, 1727.Google Scholar
9.Griffiths, T. C.Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monogram, 1975, 42, 101–04.Google ScholarPubMed
10.Griffiths, T. C. Surgical treatment of advanced ovarian cancer. In Hudson, C. N. (ed.), Ovarian cancer. Oxford: Oxford University Press, 1985, 213–18.Google Scholar
11.Griffiths, T. C. Surgery at the time of diagnosis in ovarian cancer. In Blackledge, G. & Chan, K. K. (eds.), Management of ovarian cancer. London: Butterworths, 1986, 60.Google Scholar
12.Hernandez, E., Bhagavan, B. S., Parmley, T. H., et al. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecologic Oncology, 1984, 17, 117–23.CrossRefGoogle ScholarPubMed
13.International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. American Journal of Obstetrics and Gynecology, 1987, 156, 263–64.Google Scholar
14.Khan, A., Hill, J., Grater, W., et al. Atopic hypersensitivity to cis-dichlorodiamine platinum (II) and other platinum complex. Cancer Research, 1976, 35, 2766.Google Scholar
15.Kuhn, W., Kaufmann, M., Feichter, G. E., et al. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecologic Oncology, 1989, 33, 360–67.CrossRefGoogle ScholarPubMed
16.Leonard, B., Eccleston, E., Jones, , et al. Antileukemic nephrotoxicity properties of platinum compounds. Nature (London), 1971, 43, 234.Google Scholar
17.Levin, L., & Hryniuk, W.Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. Journal of Clinical Oncology, 1987, 5, 757–67.Google Scholar
18.Marsoni, S., Torri, V., Valsecchi, M. G., et al. Prognostic factors in advanced epithelial ovarian cancer. British Journal of Cancer, 1990, 61, 444–50.CrossRefGoogle Scholar
19.McGowan, L., Lesher, L., Norris, H., et al. Mis-staging of ovarian cancer. Obstetrics and Gynecology, 1985, 65, 568–72.Google Scholar
20.Molleman, J. E., Cisplatin neurotoxicity. New England Journal of Medicine, 1990, 322, 126–27.Google Scholar
21.Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E. L., et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian cancer. Journal of Clinical Oncology, 1987, 5, 1157–68.Google Scholar
22.Ochiai, K., Takakura, S., Isonishi, S., et al. Maximal cytoreductive surgery and high dose cisplatin chemotherapy for the advanced ovarian cancer. Asia Oceania Journal of Obstetrics and Gynaecology, 1993, 19, 375–81.Google Scholar
23.Oken, M. M., Cuech, R. H., Tormey, D. C., et al. Toxicity and response criteria of the Eastern Co-operative Oncology Group. American Journal of Clinical Oncology, 1982, 5, 649–53.Google Scholar
24.Omura, G., Blessing, J., Ehrlich, C., et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer, 1986, 57, 1725–30.Google Scholar
25.Omura, G., Brady, M., Homsley, H., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group Experience. Journal of Clinical Oncology, 1991, 9, 1138–50.Google Scholar
26.Omura, G., Budny, B., Berek, J., et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 1989, 7, 457–65.CrossRefGoogle ScholarPubMed
27.Omura, G., Morrow, P., Blessing, J., et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer, 1983, 51, 783–89.Google Scholar
28.Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophos phamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. Journal of Clinical Oncology, 1991, 19, 1668–78.Google Scholar
29.Pettersson, F., Coppleson, M., Creasman, W., et al. Annual report on the results of treatment in gynecologic cancer. Vol. 20. Stockholm: International Federation of Gynecology and Obstetrics, 1986.Google Scholar
30.Redman, J., Petroni, G., Saigo, P., et al. Prognostic factors in advanced ovarian carcinoma. Journal of Clinical Oncology, 1986, 4, 515–23.Google Scholar
31.Rubin, S., Hoskins, W., Saigo, P., et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecologic Oncology, 1991, 42, 137–41.Google Scholar
32.Sevelda, P., Vavra, N., Shemper, M., et al. Prognostic factors for survival in Stage I epithelial ovarian carcinoma. Cancer, 1990, 65, 2349–52.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
33.Statistics and information department, Minister's secretariat, Ministry of Health and Welfare. Vital statistics of Japan 1991. Ministry of Health and Welfare, 1993, 1, 266–81.Google Scholar
34.Sugawa, T., Umesaki, N., Ochiai, K., et al. A group study on prognosis of ovarian cancer in Japan. Acta Obstetrica et Gynaecologica Japonica, 1992, 44, 827–32 (in Japanese).Google Scholar
35.Swenerton, K., Hislop, T., Spinelli, J., et al. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstetrics and Gynecology, 1985, 65, 264–69.Google ScholarPubMed
36.Terashima, Y., Ochiai, K., Sasaki, H., et al. Individualization of surgical treatment for ovarian cancer. Baillièire's Clinical Obstetrics and Gynaecology, 1989, 3, 73–82.Google Scholar
37.Terashima, Y., Sasaki, H., Ochiai, K., et al. Twenty one multicentral studies on prognosis of advanced ovarian cancer: Focused on correlation between primary surgical procedure following adjuvant chemotherapies and 4 year survival rates. Acta Obstetrica et Gynaecologica Japonica, 1993, 45, 363–70 (in Japanese).Google Scholar
38.Thigpen, J. T. Single agent chemotherapy in the management of ovarian carcinoma. In Alberts, D. S. & Surwit, E. A. (eds.), Ovarian carcinoma. Boston: Martinus Nijhoff, 1985, 115–46.Google Scholar
39.van Lindert, A. C. M., Alsbach, G. P. J., Barents, J., et al. Abdominal radical tumor reduction procedure. In Heintz, A. P. M., Griffiths, C. T., & Trimbos, J. B. (eds.), Surgery in gynecology. The Hague: Martinus Nijhoff, 1984, 275–87.Google Scholar
40.Young, R., Decker, D., Wharton, J. T., et al. Staging laparotomy in early ovarian cancer. Journal of the American Medical Association, 1983, 250, 3072–76.CrossRefGoogle ScholarPubMed